Bill
National Health Amendment (Technical Changes to Averaging Price Disclosure Threshold and Other Matters) Bill 2024
passed, as at 2024-09-26. Health and Aged Care portfolio.
- Sponsor
- Not recorded
- Portfolio
- Health and Aged Care
Recorded stages
- introduced — 2024-08-21
- second reading — 2024-08-21
- other — 2024-09-10
- second reading — 2024-09-10
- second reading — 2024-09-10
- other — 2024-09-11
- third reading — 2024-09-11
- introduced — 2024-09-11
- second reading — 2024-09-11
- second reading — 2024-09-19
- second reading — 2024-09-19
- third reading — 2024-09-19
- passed — 2024-09-19
- royal assent — 2024-09-26
Divisions
No divisions recorded. Most questions are decided on the voices; this does not establish that a bill was unopposed.
Plain-language summary
Written by a model from the explanatory memorandum; not the record, as at 2024-08-21.
The bill makes technical corrections to the Pharmaceutical Benefits Scheme to clarify how price reductions work for certain medicines.
It changes sections 99ADH and 99ADHC of the National Health Act 1953 to remove confusion about the 12.5 per cent average unadjusted price reduction test and what counts as a previous data collection period for designated brands.
The changes are stated to be for avoidance of doubt only and do not alter how the provisions have operated since 1 July 2022.
- Clarifies the 12.5 per cent average unadjusted price reduction test in section 99ADH.
- Defines 'previous data collection period' in section 99ADHC for designated brands.
- Confirms that all consequences of being a designated brand start on the same date.
Pharmaceutical companies responsible for medicines listed under the Pharmaceutical Benefits Scheme, and the Department of Health which administers the scheme.
Sources
em
billhome
frl act